An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 19 Sep 2017 According to an Argos Therapeutics media release, the company is planning a conference call to discuss an update on this trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 12 Sep 2017 Interim results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 According to an Argos Therapeutics media release, in April 2017 the company met with the FDA to discuss the ADAPT trial and agreed to review a protocol amendment to extend the trial beyond the originally targeted 290 events and a revised statistical analysis plan that the Company plans to submit.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top